Ring substituted and other conformationally constrained tyrosine analogs of [cyclic] [D-Pen2,D-Pen5]enkephalin with .delta.-opioid receptor selectivity

Citations Over TimeTop 10% of 1992 papers

Abstract

The conformationally restricted, cyclic disulfide-containing delta opioid receptor selective enkephalin analogue [D-Pen2,D-Pen5] enkephalin (DPDPE) was modified by 2' (CH3) and 3' (I, OCH3, NO2, NH2) ring substitutions and by beta-methyl conformationally constrained beta-methyltyrosine derivatives in the 1 position. The potency and selectivity of these analogues were evaluated by bioassay in the mouse vas deference (MVD, delta receptor assay) and guinea pig ileum (GPI, mu receptor assay) assays and by radioreceptor binding assays in the rat brain using [3H]CTOP (mu ligand) and [3H][p-ClPhe4]DPDPE (delta ligand). The analogues showed highly variable potencies in the binding assays and in the bioassays. Aromatic ring substituents with positive Hammett constants had decreased potency, while substituents with negative Hammett constraints has increased potency for the opioid receptor. The most potent and most selective compound based on the binding was [2'-MeTyr1]DPDPE (IC50 = 0.89 nM and selectivity ratio 1310 in the binding assays). The 6-hydroxy-2-aminotetralin-2-carboxylic acid-containing analogue, [Hat1]DPDPE, also was highly potent and selective in both assays, demonstrating that significant modifications of tyrosine in enkephalins are possible with maintenance of high potency and delta opioid receptor selectivity. Of the beta-methyl-substituted Tyr1 analogues, [(2S,3R)-beta-MeTyr1]DPDPE was the most potent and the delta receptor selective. The results with substitution of beta-MeTyr or Hat instead of Tyr also demonstrate that topographical modification in a conformationally restricted ligand can significantly modulate both potency and receptor selectivity of peptide ligands that have multiple sites of biological activity.

Related Papers

• → Recent advances in selective opioid receptor agonists and antagonists(2003)163 cited
• → Are μ-opioid receptor polymorphisms important for clinical opioid therapy?(2005)144 cited
• → Receptor‐selective changes in µ‐, δ‐ and κ‐opioid receptors after chronic naltrexone treatment in mice(2003)74 cited
• → Opioid-induced modification of granulocyte function(1988)25 cited
• → Problems and Approaches in Studying Membrane Opioid Receptors(1991)1 cited